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The addition of cetuximab to platinum-based chemotherapy (cisplatin or carboplatin
plus 5-fluorouracil [5-FU]), followed by maintenance cetuximab until disease progression
(EXTREME), resulted in the first regimen to yield significantly improved survival outcomes
in the first-line treatment of patients with recurrent and/or metastatic squamous cell
carcinoma of the head and neck (R/M SCCHN) in over 30 years. Currently, the EXTREME
regimen is a guideline-recommended treatment in the first-line R/M setting, and,
therefore, it is used as a control arm in all new first-line, phase 3 immunotherapy trials.
More recently, new checkpoint inhibitor approaches have emerged and are changing
the treatment landscape for PD-L1–positive patients with R/M SCCHN. Additionally,
alternative chemotherapy backbones in R/M SCCHN are continually investigated.
Replacing 5-FU with a taxane in the EXTREME regimen seeks to take advantage
of the potential immunogenic and proapoptotic synergy between cetuximab and
docetaxel or paclitaxel. These cetuximab-, platinum-, and taxane-based treatments
have demonstrated promising survival results and cytoreductive properties in single-arm
studies. Thus, these combination treatments may be of importance to patients with
high tumor burden and dangerous site involvements (e.g., causing bleeding, suffocation,
dysphagia, or ulceration), in whom symptom relief is a key treatment goal. TPExtreme
is the first large, randomized trial comparing a cetuximab, platinum, and taxane
combination regimen with EXTREME. Currently, the substitution of 5-FU with a taxane
is a feasible and clinically beneficial option for patients with contraindications to 5-FU.
The TPEx regimen appears to be a new option in first-line R/M SCCHN, with a shorter
time on CT and significantly lower toxicity than the EXTREME regimen. For patients with
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R/M disease in whom further cisplatin- or carboplatin-based treatment is unsuitable, or
whose disease has already progressed on first-line R/M therapy, treatment options such
as cetuximab plus a taxane, which capitalize on the combinative ability of the 2 agents,
can be considered. Notably, it is as of yet unknown what second-line treatments may be
suitable to follow a checkpoint inhibitor-based first-line therapy.
Keywords: cetuximab, docetaxel, paclitaxel, EXTREME, TPEx, B490, R/M SCCHN
INTRODUCTION
Cancer of the head and neck accounts for >550,000 new cases
annually worldwide (1, 2). About 90% of all head and neck
cancers are squamous cell carcinomas (SCCs) (3). The prognosis
for patients with recurrent and/or metastatic SCC of the head
and neck (R/M SCCHN) is poor, with median overall survival
(OS) of< 1 year (4). Platinum-based combination chemotherapy
had historically been the standard first-line treatment for R/M
SCCHN until, in 2008, the phase 3 EXTREME trial demonstrated
that the addition of cetuximab to cisplatin/carboplatin and
5-fluorouracil (5-FU), followed by cetuximab maintenance
treatment, significantly improved patient outcomes compared
with chemotherapy alone (5). This combination treatment
increased the overall response rate (ORR) from 20 to 36%,
prolonged median progression-free survival (PFS) from 3.3
to 5.6 months, and extended median OS from 7.4 to 10.1
months compared with chemotherapy alone (5). The EXTREME
regimen is currently a standard first-line treatment option
for patients with R/M SCCHN, as supported by international
guidelines (6). However, the current treatment landscape and
continuum of care are changing in light of recent data regarding
pembrolizumab in certain subpopulations of R/M SCCHN
(7, 8). Additionally, multiple first-line strategies are under
investigation, aiming to improve outcomes for all populations
with R/M SCCHN.
In this article, we outline the available evidence, as well as
ongoing studies, for combining cetuximab and taxane-based
chemotherapy for patients with R/M SCCHN and discuss the
implications of the known safety and efficacy findings of each.
We performed a thorough review of the literature to understand
the mode of action of taxanes and identify key published phase
2–3 clinical trials as well as retrospective studies evaluating
paclitaxel- or docetaxel-based chemotherapy in R/M SCCHN
and compared their results to those of studies that investigated
the current standard of care. Furthermore, we searched for
Abbreviations: 1L, first-line; 5-FU, 5-fluorouracil; AE, adverse event; AUC,
area under the curve; CACTUX, Cisplatin, nab-Paclitaxel, and Cetuximab;
CSPOR, Comprehensive Support Project for Oncology Research; DPD,
dihydropyrimidine dehydrogenase; ECOG PS, Eastern Cooperative Oncology
Group performance status; EXTREME, cetuximab plus cisplatin/carboplatin
plus 5-fluorouracil followed by maintenance cetuximab; GORTEC, Groupe
d’Oncologie Radiothérapie Tête Et Cou; nab-paclitaxel, albumin-bound paclitaxel;
NCT, ClinicalTrials.gov identifier; NR, nor reported; ORR, overall response rate;
OS, overall survival; PFS, progression-free survival; q2w, every 2 weeks; q3w, every
3 weeks; qw, once weekly; R/M, recurrent and/or metastatic; SCCHN, squamous
cell carcinoma of the head and neck; TPEx, cisplatin, docetaxel, and cetuximab.
ongoing phase 2–3 clinical trials on ClinicalTrials.gov and
reviewed the recommendations for R/M SCCHN in the
clinical guidelines from the National Comprehensive Cancer
Network, the Spanish Society of Medical Oncology, and the
joint European Head and Neck Society, European Society for
Medical Oncology, and European Society for Radiotherapy and
Oncology (6, 9, 10).
BIOLOGICAL RATIONALE FOR
COMBINING TAXANES AND PLATINUM
WITH CETUXIMAB
Designing combination regimens allows one to consider
molecular mechanisms and select drugs with the potential to
synergize with each other as well as to avoid the cumulative
effects of their main toxicities. Indeed, cetuximab, taxanes,
and platinum are appealing combination partners, as they
may act synergistically to induce maximal antitumor activity.
Specifically, cetuximab promotes cell cycle arrest and activation
of proapoptotic molecules (11), taxanes inhibit microtubule
disassembly (12), and platinum agents form DNA adducts (13,
14), all leading to apoptosis. These properties suggest that
the 3 agents combined may have highly additive proapoptotic
and antitumor growth effects via different molecular pathways,
thereby attacking more targets within a heterogeneous tumor
(15). Indeed, several preclinical studies of other cancer models
have demonstrated synergistic activity between cetuximab and
taxanes or taxane-like cytotoxic agents in mice as measured by
cell-kill metrics and tumor growth prevention (16). Furthermore,
preclinical models suggest that the antitumor activity of
cetuximab can synergize with platinum-mediated DNA damage
activity (11, 17), making cetuximab a suitable combination
partner for either cisplatin or carboplatin. Finally, across cancer
cell lines, cetuximab has demonstrated additive cell cycle
arrest and killing activity with cisplatin, carboplatin, oxaliplatin,
docetaxel, and paclitaxel when administered sequentially after
the chemotherapy agent (18). Overall, based on observations
in an array of preclinical models of various tumor types,
proapoptotic synergy observed between cetuximab and the
individual chemotherapy agents is widespread and may apply to
multiple indications.
Another important mechanism by which cetuximab and
taxane agents may cooperate in increased tumor cell killing is
via their immunostimulatory effects. Cetuximab elicits various
immunogenic actions in the intratumoral space, including
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natural killer cell–driven antibody-dependent cell-mediated
cytotoxicity, cytotoxic T-cell recruitment to the tumor, and
dendritic cell maturation (19), which are all thought to
contribute to the antitumor activity of the drug in SCCHN.
Because of these activities, cetuximab is considered a suitable
combination partner for immunostimulatory chemotherapy
and other immunostimulatory agents (20, 21). The available
evidence from several exploratory and preclinical studies on
the interaction between taxanes and various immune processes
is of high interest and suggests that paclitaxel and docetaxel
could cooperate with cetuximab’s activity in this respect too.
For example, patients with breast cancer who had responses
with docetaxel or paclitaxel treatment had increased immune
activity markers, including interleukin 6, and increased natural
killer and lymphokine-activated killer cell activity (22). Docetaxel
modulates cytotoxic T-cell, natural killer cell, and regulatory T-
cell populations in non-tumor-bearing mice (23), while paclitaxel
enhances dendritic cell maturation (24) and other immune
actions (25). Finally, encouraging early results from preclinical
and small clinical studies on the combination of taxanes and
vaccines suggest that taxanes can have additive immunogenic
effects with other immunostimulatory anticancer therapies (23).
Therefore, there is a strong biological and mechanistic rationale
behind combining cetuximab with a platinum and a taxane agent
when treating patients with R/M SCCHN.
THE CONTINUUM OF CARE IN
R/M SCCHN
The EXTREME regimen is a standard first-line regimen option
for fit patients with R/M SCCHN recommended by international
guidelines on the basis of the phase 3 EXTREME trial, published
in 2008 (4–6). This trial compared the efficacy and safety
of cetuximab plus cisplatin/carboplatin plus 5-FU for up to
6 cycles, followed by cetuximab maintenance until disease
progression in the first-line treatment of R/M SCCHN. The
addition of cetuximab to chemotherapy improved median PFS
by 2.3 months and median OS by nearly 3 months (to 5.6
and 10.1 months, respectively); ORR was also significantly
increased from 20% with chemotherapy alone to 36% with the
EXTREME regimen. The safety profile of the EXTREME regimen
was consistent with that expected for the administered agents,
including cardiac events (associated with 5-FU), anorexia, and
skin reactions, except for an increase in the number of patients
who developed sepsis (9 of 219 in the EXTREME arm vs.
1 of 215 in the chemotherapy-only arm) (5). The safety and
efficacy of the EXTREME regimen have been consistent in the
real world, as evidenced by multiple prospective, observational
studies, including DIRECT, ENCORE, and SOCCER (26–28).
Therefore, the EXTREME regimen is feasible for use in everyday
clinical practice.
Ongoing checkpoint inhibitor studies are reshaping
the treatment landscape for specific patient subgroups
with R/M SCCHN in the near future. For example, the
randomized phase 3 KEYNOTE-048 study evaluates first-
line treatment with pembrolizumab compared with the
EXTREME regimen. In this study, patients were randomized
to receive pembrolizumab monotherapy, pembrolizumab
plus chemotherapy (cisplatin/carboplatin plus 5-FU), or the
EXTREME regimen. Although no improvement in PFS was
demonstrated and a low ORR was observed, pembrolizumab
monotherapy demonstrated superior median OS in the
programmed cell death ligand 1 (PD-L1) combined positive
score (CPS) ≥ 20 population (14.9 months vs. 10.7 months)
compared with the EXTREME regimen in patients with R/M
SCCHN (7). The OS difference in the overall population
showed pembrolizumab to be non-inferior to EXTREME
(8). Pembrolizumab plus chemotherapy demonstrated longer
OS than EXTREME (median OS, 13.0 vs. 10.7 months) (7).
The OS differences in patients with CPS ≥ 20 (14.7 vs. 11.0
months) and CPS ≥ 1 (13.6 vs. 10.4 months) were significant.
Patients with CPS 1-19 in the pembrolizumab monotherapy
arm had a median OS of 10.8 months (HR, 0.90 [95% CI:
0.68, 1.18]). These data suggest that the OS benefit in the
KEYNOTE-048 study was driven by the patients with the highest
PD-L1 expression (7, 8, 29). As a result, pembrolizumab with
or without chemotherapy is likely to become the first-line
standard of care for patients with PD-L1–high (CPS ≥ 20) R/M
SCCHN. In contrast, the benefit of pembrolizumab therapy in
patients with PD-L1–low (CPS 1–20) or PD-L1–negative (CPS
< 1) R/M SCCHN has not been demonstrated; therefore, the
EXTREME regimen remains a standard treatment option in
these patients. Of note, however, pembrolizumab has now been
approved by the US Food and Drug Administration for first-
line treatment of patients with R/M SCCHN as monotherapy
for patients whose tumors express PD-L1 (CPS ≥ 1) or in
combination with platinum and 5-FU regardless of PD-L1
expression (29).
Patients whose disease progresses on the EXTREME regimen
are then eligible for second-line therapy, including but not
limited to single-agent chemotherapy (e.g., taxanes) (9), a
combination treatment (e.g., chemotherapy doublet), or, in
light of recent advances, checkpoint inhibitor monotherapy
(6, 30–32). Immune checkpoint inhibitors improve OS
compared with investigator’s choice of monotherapy
(cetuximab, methotrexate, docetaxel) in the second- or later-
line setting and in platinum-refractory patients (patients who
progressed within 6 months of the last dose of platinum
in the locally advanced [LA] SCCHN setting), but the
ORR remains low (13.3% with nivolumab and 14.6% with
pembrolizumab) (31, 33).
Taxanes can help expand the treatment options available in
the first line, where they can replace 5-FU in the EXTREME
regimen, as well as in second- or later-line settings and in
settings where cisplatin/carboplatin treatment is unsuitable (9),
where patients can receive cetuximab in combination with single-
agent taxane instead. Furthermore, cetuximab-based therapy,
e.g., in combination with taxanes, may become a standard
second- or later-line treatment option after disease progression
on pembrolizumab monotherapy. Finally, the combination of
taxanes with checkpoint inhibitors is also currently being
evaluated, such as in the single-arm, phase 1/2 PemDoc II study
of pembrolizumab plus docetaxel (34).
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EFFICACY OF CETUXIMAB IN
COMBINATION WITH PLATINUM AND A
TAXANE FOR FIRST-LINE R/M SCCHN
The combination of cetuximab with platinum and a taxane has
become of interest for the first-line treatment of patients with
R/M SCCHN in recent years, ever since the GORTEC 2008-
03 trial suggested that these combinations may yield improved
ORRs and favorable OS compared with the EXTREME regimen
(5, 35). Results from the large randomized TPExtreme trial of
first-line cetuximab plus platinum and a taxane vs. the EXTREME
regimen have been reported and confirm earlier evidence from
smaller randomized or single-arm studies that has suggested that
the use of first-line docetaxel or paclitaxel instead of 5-FU in
the EXTREME regimen retains the regimen’s good efficacy and
favorable safety profile in patients with R/M SCCHN (36).
The trials with available, published data are outlined in
Table 1. There were some notable differences in the taxane
selected, the chemotherapy dosage, and the administration
schedule of maintenance cetuximab between trials. Whereas
docetaxel was selected for the phase 2 GORTEC 2008-03 study
and for TPExtreme, paclitaxel was used in CSPOR-HN02, CET-
INT (B490), and CETMET, and nab-paclitaxel was used in
the phase 2, single-arm CACTUX trial (37–42). Furthermore,
whereas paclitaxel was administered at 175 mg/m2 every 3 weeks
(q3w) in the B490 and CETMET studies, CSPOR-HN02 used a
split-dose of paclitaxel (100 mg/m2 on days 1 and 8 q3w) (38–
40, 42, 43). Notably, treatment in the Japanese phase 2 CSPOR-
HN02 study could be administered in the outpatient clinic, thus
reducing time spent in the hospital and, among other things,
providing more time for patients to spend with family (39, 40).
The patient populations treated with a regimen consisting of
cetuximab, a platinum agent, and a taxane in the TPExtreme,
GORTEC 2008-03, B490, and CSPOR-HN02 studies were
somewhat comparable to the patient population of the
EXTREME study, although it is difficult to make any solid
conclusions given the many different prognostic factors
associated with drug efficacy (e.g., in-field lesions vs. metastatic
only, Eastern Cooperative Oncology Group performance status
[ECOG PS], carboplatin vs. cisplatin) (5, 35, 37–40). Notably,
a higher percentage of patients in the GORTEC 2008–03
(70.4%) and CSPOR-HN02 (82.2%) studies had metastatic
disease compared with patients in the EXTREME study (47%)
(35, 39, 40). By contrast, 50.5% of the population enrolled in
the cetuximab, platinum, and paclitaxel arm of the B490 study
had some form of metastatic disease, and only 58% of patients
in the CETMET study had metastatic disease (37, 38, 42).
Furthermore, unlike EXTREME, the TPExtreme, GORTEC
2008-03, B490, and CSPOR-HN02 studies all exclusively enrolled
patients with an ECOG PS of 0 or 1 (5, 35, 37–40). Finally, in
the B490 study, 4.4% of patients in the cetuximab, platinum, and
paclitaxel arm had previously received cetuximab treatment in
the LA setting (37, 38). In agreement with the literature, human
papillomavirus status was prognostic in all studies that tested for
it and had patient samples large enough to draw conclusions on
this topic.
The GORTEC 2008-03, B490, CETMET, and CSPOR-HN02
studies all met their primary endpoints. In these studies, clinical
efficacy of the treatment of patients with first-line R/M SCCHN
did not appear to be compromised upon the substitution of 5-FU
with a taxane in the EXTREME regimen (Table 1): Median PFS
ranged from 5.2 to 7.0 months, which is in alignment with the
median PFS observed in the EXTREME phase 3 trial (5.6months)
(5, 35, 37–40, 42). Survival was also consistent between trials,
with median OS ranging from 10.2 to 14.7 months (5, 35, 37–
40, 42). Finally, response rates may potentially be higher with
this modified regimen: ORRs ranged from 40.0 to 51.7% when
5-FU was replaced with a taxane in the EXTREME regimen
(5, 35, 37–40).
The topline findings from TPExtreme were presented at the
2019 American Society of Clinical Oncology Annual Meeting
(36). Median OS for the TPEx vs. EXTREME arms was not
significantly different (14.5 vs. 13.4 months; HR, 0.87 [95% CI,
0.71–1.05]; p = 0.15); but the OS in the EXTREME arm was
unexpectedly higher than historical randomized data, leading to
a decrease in the trial power (36, 44). However, the TPEx regimen
was significantly better tolerated than the EXTREME regimen.
In summary, although treatment regimens differ by selection
of taxane and sometimes dose, the survival and safety results
appear consistent from study to study. While the survival,
response, and manageable safety profile of the regimens studied
in the GORTEC 2008-03, B490, CETMET, and CSPOR-HN02
studies are promising, we eagerly anticipate the full published
results of the ongoing European randomized TPExtreme trial,
which directly compares the TPEx and EXTREME regimens,
within the coming year (44). A detailed list of ongoing studies
is provided in Table 2.
SAFETY AND ADMINISTRATION
DIFFERENCES BETWEEN TAXANES AND
5-FU IN COMBINATION WITH CETUXIMAB
As discussed, the combination of cetuximab, platinum, and
a taxane has been shown in smaller studies to have survival
comparable to that of the EXTREME regimen. Importantly, as
5-FU and taxanes have distinct associated toxicities, they can
be used to treat different patient subgroups with R/M SCCHN
with specific contraindications to chemotherapy agents while
maintaining optimal efficacy. Indeed, observational studies have
showed that physicians do not include 5-FU in 14–45% of
therapeutic plans, indicating that 5-FU is not systematically
prescribed as part of the EXTREME regimen, likely due to
differences in its safety profile and administration (26, 27).
The TPExtreme study results showed that replacing 5-FU with
taxanes led to a better safety profile.
Safety Profiles
5-FU has been associated with a high risk of severe toxicity
in patients with dihydropyrimidine dehydrogenase [DPD;
the enzyme that catabolizes 5-FU (45)] deficiency (3–5%
occurrence rate in the general population) (46) and is therefore
contraindicated in this patient population. Therefore, patients
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TABLE 1 | Efficacy of cetuximab + platinum + taxane regimens in first-line R/M SCCHN studies.
Study No. of Patients Regimen ORR, % PFS, months OS, months
GORTEC 2008-03
(TPEx) (35)
54 Cetuximab (400 mg/m2 → 250 mg/m2 qw)
+ cisplatin (75 mg/m2 q3w)
+ docetaxel (75 mg/m2 q3w)
+ G-CSF (150 µg/m2 q3w)
Maintenance: cetuximab (500 mg/m2 q2w)
51.9 6.2 14.0
CET-INT (B490)
(37, 38)
201 Cetuximab (400 mg/m2 → 250 mg/m2 qw)
+ cisplatin (100 mg/m2 q3w) (n = 100)
Maintenance: cetuximab (250 mg/m2 qw)
vs.
Cetuximab (400 mg/m2 → 250 mg/m2) +
cisplatin (75 mg/m2 q3w) + paclitaxel (175
mg/m2 q3w) (n = 91)
Maintenance: cetuximab (250 mg/m2 qw)
41.8
vs.
51.7
6.0
vs.
7.0
13.0
vs.
11.0
CSPOR-HN02
(39, 40)
45 Cetuximab (400 mg/m2 → 250 mg/m2 qw)a
+ carboplatin (AUC 2.5 on days 1 and 8 q3w,
up to 6 cycles) + paclitaxel (100 mg/m2 on
days 1 and 8)
Maintenance: cetuximab (250 mg/m2 qw)
40.0 5.2 14.7
NCT02270814
(CACTUX) (41)
32 Cetuximab (400 mg/m2 → 250 mg/m2 qw) +
cisplatin/carboplatin (75 mg/m2 q3w/AUC 5,
respectively) + nab-paclitaxel (100 mg/m2 qw)
Maintenance: cetuximab (250 mg/m2 qw) +
nab-paclitaxel (100 mg/m2 qw)
63.0b 6.8b 18.8b
NCT01830556
(CETMET) (42)
85 Cetuximab (400 mg/m2 → 250 mg/m2 qw) +
carboplatin (AUC 5) + paclitaxel (175 mg/m2
q3w)
Maintenance: cetuximab (500 mg/m2 q2w)
vs.
Cetuximab (400 mg/m2 → 250 mg/m2 qw) +
cisplatin/carboplatin (100 mg/m2 q3w/AUC 5,
respectively) + 5-FU (1,000 mg/m2/24 h for
96-h continuous infusions)
Maintenance: cetuximab (500 mg/m2 q2w)
51.2
vs.
47.6
6.5
vs.
4.4
10.2
vs.
8.4
5-FU, 5-fluorouracil; AUC, area under the curve; CACTUX, Cisplatin, nab-Paclitaxel, and Cetuximab; CSPOR, Comprehensive Support Project for Oncology Research; G-CSF,
granulocyte colony-stimulating factor; GORTEC, Groupe d’Oncologie Radiothérapie Tête Et Cou; nab-paclitaxel, albumin-bound paclitaxel; NCT, ClinicalTrials.gov identifier; ORR, overall
response rate; OS, overall survival; PFS, progression-free survival; q2w, every 2 weeks; q3w, every 3 weeks; qw, once weekly; R/M SCCHN, recurrent and/or metastatic squamous cell
carcinoma of the head and neck; TPEx, cisplatin, docetaxel, and cetuximab.
aCetuximab qw approved in Japan until disease progression or unacceptable toxicities.
bResults from a planned interim analysis of the CACTUX trial.
with DPD deficiency should instead be redirected to receive a
taxane as a substitute.
Grade ≥ 3 cardiac toxicity was reported in the EXTREME
trial in 7% of patients (5), which is consistent with the known
cardiac toxicity of 5-FU. Although some cardiac events can be
associated with taxanes as well (discussed below), the panel of
cardiac adverse events (AEs) differs between 5-FU and taxanes.
The most commonly described cardiotoxic effects of 5-FU are
angina and ischemic events, with a frequency of ≤ 68% in
the literature (47). A literature review spanning the years 1969
to 2007 including 377 patients treated with 5-FU reported the
frequency of specific cardiotoxic events, including myocardial
infarction (22%) and arrhythmias (23%) (48). Instances of
sudden death and thromboembolism have also been reported in
association with high-dose infusional 5-FU (49). Finally, risk of
hypotension secondary to cardiological complications, especially
in patients living in geographic regions with hot climates, could
prevent effective renal clearance of the cisplatin component
included in the treatment regimen, potentially exacerbating
cisplatin-associated toxicities in parallel. In contrast, the most
common cardiac event associated with taxane treatment is
arrhythmia, and more specifically, bradyarrhythmia, which has
been reported in <0.1–31% of patients receiving paclitaxel.
Ischemia has been reported in <1–5% of patients receiving
paclitaxel and 1.7% of those receiving docetaxel (47, 50, 51).
Finally, no documented rate of thromboembolic events with
either docetaxel or paclitaxel has been published (52). Because the
majority of cardiac events secondary to chemotherapy treatment
are unpredictable and potentially fatal, cardiac toxicity is an
important consideration for patient selection when prescribing
chemotherapy regimens.
Taxanes are associated with a different set of characteristic
AEs. Hypersensitivity reactions, a known AE with taxanes, have
been reported to occur in approximately 10% of patients (53).
Therefore, steroids are required to reduce allergic reactions
when administering taxanes (54, 55). In addition, depending on
patient age and the regimen combination itself, administration
of granulocyte colony-stimulating factor may be required to
reduce the risk of neutropenia (54, 55). Indeed, the B490 and
CSPOR-HN02 studies noted higher rates of grade 3–4 non-febrile
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TABLE 2 | Ongoing studies of cetuximab + platinum + taxane regimens in first-line R/M SCCHN.
Study Estimated
enrollment
Regimen Primary
endpoint
Results
expected/presented
NCT02268695
(TPExtreme;
randomized trial)
N = 540
1L R/M SCCHNa
Countries:
France
Germany
Spain
Cetuximab (400 mg/m2 → 250 mg/m2 qw) +
cisplatin (75 mg/m2 q3w) + docetaxel (75 mg/m2
qw) + G-CSF (150 µg/m2 q3w)
Maintenance: cetuximab (500 mg/m2 q2w)
vs.
Cetuximab (400 mg/m2 → 250 mg/m2 qw) +
cisplatin (100 mg/m2 q3w) + 5-FU (1000
mg/m2/24 h for 96-h continuous infusions)
Maintenance: cetuximab (250 mg/m2 qw)
OS December 2018/
preliminary results
presented June 2019
NCT02124707
(phase 2)
N = 38
1L R/M SCCHNa,b
Countries:
United States
Cetuximab (400 mg/m2 → 250 mg/m2 qw) +
carboplatin (AUC 2) + paclitaxel (135 mg/m2 qw)
Maintenance: cetuximab (250 mg/m2 qw)
OS February 2020
NCT02270814
(CACTUX; phase 2) (41)
N = 70
1L R/M SCCHNc
Countries:
United States
Cetuximab (400 mg/m2 → 250 mg/m2 qw) +
cisplatin/carboplatin (75 mg/m2 q3w/AUC 5,
respectively) + nab-paclitaxel (100 mg/m2 qw)
Maintenance: cetuximab (250 mg/m2 qw) +
nab-paclitaxel (100 mg/m2 qw)
PFS May 2021
NCT01437449
(TPC regimen; phase 2)
N = 27
1L R/M SCCHNc
Countries:
United States
Cetuximab (400 mg/m2 → 250 mg/m2 qw) +
cisplatin (30 mg/m2 qw) + docetaxel (30 mg/m2
qw)
Maintenance: Unspecified
ORR January 2021
UMIN000015405d
(TEMPER study; phase
2)
N = 180
1L R/M SCCHNa
Cetuximab + carboplatin + docetaxel
vs.
Cetuximab + cisplatin + 5-FU
N/A
1L, first-line; 5-FU, 5-fluorouracil; AUC, area under the curve; CACTUX, Cisplatin, nab-Paclitaxel, and Cetuximab; G-CSF, granulocyte colony-stimulating factor; LA, locally advanced;
nab-paclitaxel, albumin-bound paclitaxel; N/A, not available; NCT, ClinicalTrials.gov identifier; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; q3w, every 3
weeks; qw, once weekly; R/M SCCHN, recurrent and/or metastatic squamous cell carcinoma of the head and neck; TPC, docetaxel, cisplatin, and cetuximab; TPEx, cisplatin, docetaxel,
and cetuximab.
aEither previously untreated or progressed on therapy in the LA setting 6+ months ago.
bHistory of prior cumulative exposure to >300 mg/m2 cisplatin, AUC of 18 of carboplatin, or their combined equivalent within 1 year prior to enrollment was an exclusion criterion.
cEither previously untreated or completed therapy in the LA setting 3–4+ months ago.
dDosing information not available.
neutropenia (42% [grade ≥ 3] and 68%, respectively), compared
with those observed in EXTREME in both treatment arms
(22–23%) (5, 37–40). Additionally, dependent upon the dose
administered, the schedule of administration, and the duration
of the infusion, neurotoxicity has been reported with paclitaxel
(56). Thus, patients with preexisting neurological conditions may
be better suited to receive 5-FU.
A detailed list of AEs in the GORTEC 2008-03,
B490, CETMET, and CSPOR-HN02 studies is presented
in Table 3. Although tolerance and compliance were
significantly improved with the TPEx regimen compared
with EXTREME, full safety results of this trial have not yet been
published (36).
Administration Differences
In addition to known differences in their safety profiles,
taxanes and 5-FU require different considerations in terms
of administration as well as prophylactic and reactive AE
management. Whereas a taxane can be administered in short
infusions (3 h; paclitaxel, 175 mg/m2 q3w; docetaxel, 75 mg/m2
q3w), 5-FU requires a 4- to 5-day continuous infusion (1,000
mg/m2/d) in every chemotherapy cycle. Furthermore, the
cisplatin dose used in the EXTREME regimen (100 mg/m2
q3w) is higher compared with that used in combination with
taxanes (75 mg/m2 q3w) (5, 37, 38). Historically, patients
have been hospitalized for the duration of the 5-FU infusion
(resulting in increased costs), and this was highly inconvenient
for both the patient and the institution (39). More recently,
subcutaneously implanted “port” catheters and portable pumps
have become an option allowing administration of 5-FU in the
outpatient setting; however, the pumps require a peripherally
inserted central venous line, which in turn can put the patient
at risk for complications during use (≈ 25% of cases) or be
associated with failure of line removal (≈ 15% of cases) as well
as infections of the exit site and bloodstream (at a rate of ≈ 3
and ≈ 2%, respectively) (57). Indeed, most patients continue to
require hospitalization for continuous infusion of 5-FU, leading
to decreased quality of life for the patient via less time spent
with family and inconveniences due to the availability of access
to hospital facilities. By contrast, patients using portable pumps
still have to return to the hospital at the end of the 4-day
infusion. This can be viewed as either an inconvenience to the
patient because of an additional hospital visit or as an advantage
because the patient can be examined for any issues (e.g., renal
insufficiency) by a specialized practitioner, thus reducing the risk
of undetected problems.
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TABLE 3 | Safety profile of cetuximab + platinum + taxane: grade ≥ 3 AEs
occurring in ≥ 5% of patients in the cetuximab + platinum + taxane arm.
Incidence in each study, %
AE GORTEC
2008–03 (TPEx)
(35)
(N = 54)
CET-INT (B490)
(37, 38)
(n = 91)
CSPOR-HN02
(39, 40)
(N = 47)
Total NR 72.5 NR
Hematologic events
Non-febrile 20.4 41.8 68.1
neutropenia
Febrile neutropenia 7.4 6.6 8.5
Leukopenia 3.7 29.7 NR
Lymphopenia 3.7 5.5 NR
Anemia 3.7 6.6 6.4
Non-hematologic
events
Fever/infection 7.4 8.8 NR
Hyponatremia and 5.6 2.2, 4.4 4.3
hypokalemia
Hypersensitivity 5.6 NR NR
Oral mucositis 3.7 4.4 2.1
Asthenia/fatigue 3.7 26.4 NR
Anorexia 3.7 0.0 6.4
Skin toxicities 16.7
Skin rash NR 15.4 NR
Skin reaction NR NR 14.9
AE, adverse events; CSPOR, Comprehensive Support Project for Oncology Research;
GORTEC, Groupe d’Oncologie Radiothérapie Tête Et Cou; NR, not reported.
In summary, although the EXTREME regimen is a
longstanding first-line treatment option for R/M SCCHN,
patients with preexisting cardiac problems, DPD deficiencies,
and other risk factors may be more suited to receive a taxane
than 5-FU during first-line combination therapy. Indeed,
optimizing the first-line management of R/M SCCHN via
appropriate patient selection is not only important for
the patient’s quality of life, but it is also necessary to help
maintain the patient’s ECOG PS and fitness upon disease
progression to allow for additional therapies in the second- and
later-line settings.
USES OF CETUXIMAB PLUS A TAXANE
Patients whose disease has progressed on the EXTREME regimen
or who have platinum-refractory disease have several remaining
treatment options, including single-agent chemotherapy
(docetaxel, methotrexate) and checkpoint inhibitor therapy
(nivolumab, pembrolizumab). For patients with PD-L1–high
tumors whose disease progresses on first-line pembrolizumab
monotherapy, the EXTREME regimen or TPEx regimen will
likely become a second-line treatment option. As cetuximab
plus either docetaxel or paclitaxel has shown efficacy as second-
or later-line treatment in patients with R/M SCCHN, this
combination may be a suitable treatment option for patients
with disease progression on first-line pembrolizumab plus
platinum-based chemotherapy.
Cisplatin/Carboplatin-Unsuitable or Poor
PS R/M SCCHN
Patients entering or progressing in the R/M SCCHN continuum
of care for whom a platinum-based chemotherapy regimen
is not suitable due to a poor ECOG PS, contraindication, or
too-short time to recurrence since the last dose of platinum
(e.g., treatment-free interval <6 months) are not eligible to
receive the EXTREME regimen and thus require an alternative
treatment approach. A cetuximab-taxane regimen could confer
benefit in this patient population. Indeed, the combination of
cetuximab plus docetaxel or paclitaxel has been shown to have
a manageable safety profile and promising efficacy in various
prospective and retrospective studies of patients with either first-
line or platinum-refractory R/M SCCHN (Table 4) (2, 58–60).
Although these studies had small numbers of enrolled patients
and were single arm or retrospective, the results suggested
that patient selection for cetuximab-plus-taxane combinations
in the settings of cisplatin/carboplatin unsuitability or poor PS
may result in high ORRs and disease control in certain poor-
prognosis populations. Currently, no further investigations of
the combination of cetuximab plus a taxane in patients who
are unable to receive cisplatin, carboplatin, or an aggressive
chemotherapy regimen are being conducted.
Later-Line R/M SCCHN
Some single-center or retrospective studies have provided
evidence for the use of cetuximab plus a taxane in later-line
R/M SCCHN. Unfortunately, these studies enrolled patients
in various lines of treatment, with patients with R/M SCCHN
in cisplatin/carboplatin-unsuitable, second-, and later-line
settings all receiving the same treatment and analyzed as a
pooled data set, thereby confounding interpretation of survival
outcomes between trials and regimens. A single-arm trial of
59 patients receiving cetuximab and paclitaxel, of whom 75%
were previously untreated in the R/M setting, yielded an ORR of
47.5% and median PFS and OS of 7.7 months and 13.2 months,
respectively (61). Sosa et al reported an ORR, median PFS, and
median OS of 55%, 4.0 months, and 10.0 months, respectively, in
33 patients in whom first-line platinum-based therapy had failed
(62). Similarly, Jimenez et al described a study of 22 patients
with second-line or cisplatin/carboplatin-unsuitable R/M disease
who were treated with cetuximab and paclitaxel and achieved an
ORR of 55% (95% CI, 31–76%), a median PFS of 5.4 months, and
a median OS of 9.1 months (63). Finally, Peron et al reported
an ORR of 38%, median PFS of 3.9 months, and OS of 7.6
months in a cohort of 42 patients with second-line R/M SCCHN
(64). Taken together, the results of the available retrospective
studies of cetuximab-plus-taxane regimens align with what
has been observed in single-arm and randomized, prospective
trials, seemingly independent of mixed cisplatin/carboplatin-
unsuitable, second- or later-line settings. Although findings still
need to be validated in the randomized, prospective setting, the
combination of cetuximab and a taxanemay be a viable treatment
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TABLE 4 | Studies of cetuximab + taxane–only regimens.
Study No. of patients, setting Regimen ORR, % PFS, months OS, months
PROSPECTIVE
Hitt et al. (58);
phase 2
n = 46
1L R/M SCCHNa
Cetuximab (400 mg/m2 → 250 mg/m2 qw) +
paclitaxel (80 mg/m2 qw) until progression or
unacceptable toxicity
54 4.2 8.1
Knoedler et al. (2);
phase 2
n = 84
All patients had prior platinum
therapy but no prior cetuximab
Cetuximab (400 mg/m2 → 250 mg/m2 qw) +
docetaxel (35 mg/m2 qw)
Maintenance: cetuximab 250 mg/m2 qw
11 3.1 6.7
RETROSPECTIVE
Posch et al. (59) n = 31
1L R/M SCCHN, unselected
Cetuximab (500 mg/m2 ) + docetaxel (50
mg/m2) q2w
13 4.0 8.3
Bernad et al. (60) n = 148
Mostly unfit for aggressive
therapy (including EXTREME)
Cetuximab (400 mg/m2 → 250 mg/m2 qw) +
paclitaxel (80 mg/m2 qw)
47 7 10
1L, first-line; LA, locally advanced; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; qw, once weekly; R/M SCCHN, recurrent and/or metastatic squamous
cell carcinoma of the head and neck.
aEither previously untreated or progressed on therapy in the LA setting 6+ months ago.
option for patients with platinum-refractory or second-
line disease. Additionally, follow-up therapies after patients
progress on checkpoint inhibitor-based treatment remain to be
adequately investigated.
CONCLUSIONS
The substitution of 5-FU with a taxane is being investigated as
a potential method to further improve survival and response
rates in first-line R/M SCCHN. Such combination regimens can
take advantage of the ability of cetuximab to synergize antitumor
activity with platinum and taxane agents, as demonstrated in
preclinical studies. Available evidence suggests that cetuximab
plus platinum and a taxane is a more favorable combination with
efficacy similar to that of the EXTREME regimen and a favorable
safety profile in patients with R/M SCCHN. Indeed, it appears
that this combination may further improve on the ORR of the
EXTREME regimen with similar survival outcomes (36). The
landscape in R/M SCCHN is evolving, and the first-line standard
of care is becoming fragmented due to newly available treatment
options, e.g., for the population with PD-L1–high disease. Other
patients, such as those with PD-L1–low and PD-L1–negative
tumors and those with high tumor burden, are more likely to
benefit from cetuximab plus platinum-based chemotherapy. The
TPEx regimen is a first-line treatment option for patients with
R/M SCCHN. For patients with a high risk of toxicity with 5-
FU, TPEx and related regimens present an interesting treatment
approach with efficacy similar to that of the EXTREME regimen.
Additionally, patients unable to receive cisplatin- or carboplatin-
based chemotherapy, or those with poor prognosis or later-
line R/M SCCHN, are suitable candidates for cetuximab plus
paclitaxel or docetaxel treatment as well as other available therapy
options (e.g., checkpoint inhibitors, single-agent chemotherapy).
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